HLS Therapeutics Inc has seen a notable increase in its stock price, closing up 2.33% in the last trading session.
HLS Therapeutics Inc (HLS.TO) experienced a positive trading day, with shares climbing to CA$4.40. This uptick reflects investor confidence, especially following the company's recent financial performance and strategic initiatives.
Investor takeaway: Investors may find HLS Therapeutics appealing, particularly due to its recent revenue growth and improved operational cash flow, which suggest a potentially brighter future for the company's stock.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$132.29M
52W high
$5.76
52W low
$4.00
1W change
-3.72%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 77.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.33
+77.0% Upside
Current Price
C$4.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.5%
Annualized
90-Day Vol
22.5%
Annualized
Trend (90d)
-48.8%
Annualized drift
90d Mean
C$3.48
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.91 | C$3.53 โ C$4.32 |
| 60 trading days | C$3.69 | C$3.19 โ C$4.26 |
| 90 trading days | C$3.48 | C$2.92 โ C$4.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc stock rises 2.33% in one day
The stock's market cap now stands at CA$136 million, reflecting growing investor interest.
Bull case
The company's recent financial results show a solid upward trend, with a 15% increase in Vascepa net sales and an impressive 80% rise in cash from operations. This performance could attract further investment and drive the stock price higher.
Bear case
Despite the positive movement, HLS Therapeutics still operates at a loss, with a profit margin of -0.1846. Investors should remain cautious about the company's long-term profitability and market conditions.
Recent Financial Performance
HLS Therapeutics recently reported a 2% year-over-year increase in revenue for Q1 2026, amounting to CA$12.9 million. Notably, net sales of Vascepa grew by 15%, indicating strong demand for their products. This positive trend in revenue and cash flow may have contributed to the stock's rise.
Market Sentiment and Investor Confidence
The rise in HLS Therapeutics' stock price can also be attributed to improved investor sentiment. With a market cap of CA$136 million and a substantial increase in cash from operations, investors likely view the company as a more stable investment. The reaffirmation of their 2026 financial guidance further solidifies this confidence.
Advertisement
